CVA Family Office LLC Purchases Shares of 2,592 Aflac Incorporated (NYSE:AFL)

CVA Family Office LLC purchased a new stake in Aflac Incorporated (NYSE:AFLFree Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,592 shares of the financial services provider’s stock, valued at approximately $214,000.

A number of other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of Aflac during the fourth quarter worth $175,416,000. Invesco Ltd. boosted its holdings in Aflac by 62.4% in the 1st quarter. Invesco Ltd. now owns 4,936,608 shares of the financial services provider’s stock valued at $317,865,000 after purchasing an additional 1,897,212 shares during the period. Morgan Stanley boosted its holdings in Aflac by 22.9% in the 4th quarter. Morgan Stanley now owns 8,812,956 shares of the financial services provider’s stock valued at $634,004,000 after purchasing an additional 1,640,984 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Aflac during the 4th quarter worth approximately $72,249,000. Finally, Barclays PLC increased its holdings in shares of Aflac by 67.3% during the second quarter. Barclays PLC now owns 1,712,568 shares of the financial services provider’s stock worth $119,539,000 after purchasing an additional 689,173 shares during the period. Institutional investors own 66.75% of the company’s stock.

Insider Transactions at Aflac

In other news, Director Masatoshi Koide sold 30,493 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the transaction, the director now owns 86,090 shares of the company’s stock, valued at approximately $6,879,451.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Masatoshi Koide sold 30,493 shares of Aflac stock in a transaction on Friday, February 16th. The shares were sold at an average price of $79.91, for a total value of $2,436,695.63. Following the completion of the sale, the director now owns 86,090 shares of the company’s stock, valued at approximately $6,879,451.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Thomas J. Kenny sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total transaction of $423,100.00. Following the transaction, the director now owns 17,920 shares in the company, valued at approximately $1,516,390.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,493 shares of company stock worth $3,765,706. Company insiders own 0.90% of the company’s stock.

Aflac Stock Performance

NYSE AFL opened at $84.16 on Monday. The company has a market capitalization of $48.56 billion, a price-to-earnings ratio of 10.86, a PEG ratio of 2.30 and a beta of 0.91. Aflac Incorporated has a twelve month low of $61.30 and a twelve month high of $86.20. The stock has a fifty day simple moving average of $81.57 and a 200 day simple moving average of $80.60. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33.

Aflac (NYSE:AFLGet Free Report) last issued its quarterly earnings data on Thursday, February 1st. The financial services provider reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.22). Aflac had a return on equity of 17.59% and a net margin of 24.92%. The company had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $4.44 billion. During the same quarter last year, the business earned $1.29 earnings per share. Sell-side analysts expect that Aflac Incorporated will post 6.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. UBS Group raised their price objective on Aflac from $80.00 to $84.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 10th. The Goldman Sachs Group boosted their price target on Aflac from $61.00 to $75.00 and gave the company a “sell” rating in a research note on Tuesday, January 9th. Raymond James increased their price objective on shares of Aflac from $83.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Wells Fargo & Company increased their price target on shares of Aflac from $82.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 6th. Finally, StockNews.com downgraded shares of Aflac from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $80.36.

Read Our Latest Report on Aflac

Aflac Company Profile

(Free Report)

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.

Read More

Institutional Ownership by Quarter for Aflac (NYSE:AFL)

Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.